Log in to save to my catalogue

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding...

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_856778817

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Publication information

Publisher

Kidlington: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3–5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen. Methods...

Alternative Titles

Full title

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_856778817

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_856778817

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(10)62175-7

How to access this item